{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:23:27Z","timestamp":1777551807472,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["DIGITAL HEALTH"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a chronic condition causing gastrointestinal inflammation. Digital health tools like the Tami app support symptom tracking, medication adherence, and personalized care. This study examines demographics, clinical characteristics, medication use, and symptom and patient-reported outcome (PRO) tracking behaviors among Tami app users in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis included data from 2059 users aged \u226518 who registered between June 2023 and December 2024. Demographics, clinical characteristics, medication usage, and symptom\/PRO tracking behavior were assessed. Group differences were analyzed using chi-square tests. Medications were categorized as conventional (aminosalicylates, azathioprine, methotrexate, corticosteroids, calcineurin inhibitors), advanced (biologics, small molecules), or other (painkillers, antidiarrheals, and vitamins\/supplements).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 2059 users (mean age: 34.5 years; 73.8% female), 49.4% had ulcerative colitis (UC) and 49.2% had Crohn's disease (CD). Conventional therapies were used by 60.0% and advanced therapies by 57.1%. CD patients were more likely to use advanced therapies (70.0%) than conventional treatments (43.5%) (\u03c7\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u2009143.5,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Users diagnosed 3\u20135 years earlier had higher advanced therapy use (\u03c7\n                      <jats:sup>2\u2009<\/jats:sup>\n                      =\u200990.1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.0001) and lower conventional therapy use (\u03c7\n                      <jats:sup>2\u2009<\/jats:sup>\n                      =\u200944.1,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.0001) than those diagnosed within 2 years. Younger users (18\u201325 years) and those recently diagnosed (0\u20132 years) were more likely to track symptoms. The most frequently tracked PRO was the Treatment Satisfaction Questionnaire for Medication 9.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Tami app is primarily used by younger, female IBD patients. Symptom tracking is highest among younger and recently diagnosed users. These findings underscore the app's potential as a digital tool to support IBD management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552076261418855","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:45:42Z","timestamp":1772117142000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective analysis of characteristics of Tami users, a digital patient companion for inflammatory bowel disease"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-6731","authenticated-orcid":false,"given":"Ann-Sophie","family":"Stratil","sequence":"first","affiliation":[{"name":"Temedica GmbH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2198-9925","authenticated-orcid":false,"given":"Benjamin","family":"Friedrich","sequence":"additional","affiliation":[{"name":"Temedica GmbH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6541-3795","authenticated-orcid":false,"given":"Tim","family":"Hahn","sequence":"additional","affiliation":[{"name":"Institute for Translational Psychiatry, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7776-8709","authenticated-orcid":false,"given":"Andreas","family":"L\u00fcgering","sequence":"additional","affiliation":[{"name":"MVZ Portal 10, M\u00fcnster, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9849-8403","authenticated-orcid":false,"given":"Steffeni","family":"Papukchieva","sequence":"additional","affiliation":[{"name":"Temedica GmbH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx100"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0b013e318281f395"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-023-03435-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30333-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001545"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.2196\/51408"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31711-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.4127"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.2196\/34882"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.962605"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaf108"},{"key":"e_1_3_3_15_2","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie Verdauungs- und Stoffwechselkrankheiten (DGVS). Aktualisierte S3-Leitlinie \u201cDiagnostik und Therapie des Morbus Crohn\u201d. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/021-004 (2021 accessed 11 September 2024)."},{"key":"e_1_3_3_16_2","unstructured":"Deutsche Gesellschaft f\u00fcr Gastroenterologie Verdauungs- und Stoffwechselkrankheiten (DGVS). Aktualisierte S3-Leitlinie Colitis ulcerosa https:\/\/register.awmf.org\/de\/leitlinien\/detail\/021-009 (2021 accessed 11 September 2024)."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad183"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-010-1397-9"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10916-021-01706-x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0272-8"}],"container-title":["DIGITAL HEALTH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076261418855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552076261418855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552076261418855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:55:58Z","timestamp":1777398958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552076261418855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":19,"alternative-id":["10.1177\/20552076261418855"],"URL":"https:\/\/doi.org\/10.1177\/20552076261418855","relation":{},"ISSN":["2055-2076","2055-2076"],"issn-type":[{"value":"2055-2076","type":"print"},{"value":"2055-2076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"article-number":"20552076261418855"}}